Physician profile
George Tweddel
NPI 1013928647
$1,835.08
in general payments reported to CMS, 2019-2025
28 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $87.63 · 2021: $95.33 · 2022: $344 · 2023: $180 · 2024: $320 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $316.00 | 2019 | |
| Medtronic, INC. | $240.68 | 2021-2025 | Truclear |
| Astellas Pharma US INC | $130.17 | 2024-2025 | Veozah |
| Hologic Sales and Service, LLC | $116.66 | 2024-2025 | Myosure Tissue Removal Device, Aptima, Fluent Fluid Management System |
| Sumitomo Pharma America, INC. | $112.32 | 2023-2025 | Myfembree, Gemtesa |
| Amag Pharmaceuticals, INC. | $85.87 | 2019 | |
| Mayne Pharma Commercial LLC | $80.99 | 2022-2025 | |
| Abbvie INC. | $78.49 | 2022-2023 | Lo Loestrin Fe |
| Evofem Biosciences, INC. | $76.90 | 2021-2023 | Phexxi |
| Bayer Healthcare Pharmaceuticals INC. | $74.31 | 2022-2024 | |
| Daiichi Sankyo INC. | $73.20 | 2019-2023 | Injectafer |
| Therapeuticsmd, INC. | $55.77 | 2019-2020 | |
| Pfizer INC. | $46.57 | 2019-2025 | |
| Avion Pharmaceuticals | $40.12 | 2020-2021 | |
| Alydia Health | $33.09 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $31.67 | 2022 | |
| Coopersurgical, INC. | $30.51 | 2022-2023 | Paragard T 380a |
| Exeltis, USA INC. | $28.85 | 2020-2022 | |
| Novo Nordisk INC | $27.37 | 2025 | Wegovy |
| Allergan, INC. | $26.67 | 2019 | |
| Millicent US INC | $24.90 | 2019-2020 | |
| Lilly USA, LLC | $18.17 | 2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $16.19 | 2024 | Gardasil, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $16.14 | 2023 | Seglentis |
| Vertical Pharmaceuticals, LLC | $14.97 | 2019 | |
| Amgen INC. | $14.16 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $12.88 | 2019 | |
| Minerva Surgical, INC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Tweddel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.